Khiron Life Sciences Corp. Stock price

Equities

KHRN.H

CA49374L3065

Pharmaceuticals

Delayed Toronto S.E. 10:54:46 2023-05-05 am EDT 5-day change 1st Jan Change
0.04 CAD -.--% Intraday chart for Khiron Life Sciences Corp. -.--% -.--%
Sales 2020 8.02 10.86 Sales 2021 12.8 17.33 Capitalization 37.61M 50.94M
Net income 2020 -24M -32.5M Net income 2021 -33M -44.69M EV / Sales 2020 6,378,653 x
Net cash position 2020 5.38M 7.29M Net cash position 2021 6.7M 9.07M EV / Sales 2021 2,416,458 x
P/E ratio 2020
-1.88 x
P/E ratio 2021
-1.04 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 95.36%
More Fundamentals * Assessed data
Dynamic Chart
Colombia's cannabis industry in crisis over regulatory, political hurdles RE
2518542 Alberta Ltd completed the acquisition of Khiron Europe Gmbh, Zerenia Clinics Limited, Khiron Life Sciences Spain SL, Khiron Life Sciences Uk and Pharmadrug Production GmbH from Khiron Life Sciences Corp.. CI
2518542 Alberta Ltd agreed to acquire Khiron Europe Gmbh, Zerenia Clinics Limited, Khiron Life Sciences Spain SL, Khiron Life Sciences Uk and Pharmadrug Production GmbH from Khiron Life Sciences Corp. for CAD 3 million. CI
Khiron Life Sciences Corp. Enters into Partnership with an Accredited 3rd Party Contract Manufacturing Organization CI
Khiron Life Sciences Brief: On Filing of Audited Annual Financial Statements, Co Says Won't Make It On Or Before the Prescribed Deadline of May 1, 2023, as a Result of the Change in CFO MT
Khiron Life Sciences Brief: Appointing Michael O'Connor as Chief Financial Officer, Replacing Ms. Helen Bellwood MT
Khiron Life Sciences Announces CFO Changes CI
Toronto Stocks Climb; TerrAscend Rises on Plans to Apply for TSX Listing DJ
Khiron Life Sciences Plans Overnight Marketed Offering of Share Units MT
Khiron Life Sciences Secures Additional Loan with Investment-Grade Bank MT
Khiron Life Sciences Corp. Announces That Its Wholly Owned Subsidiary Zerenia Colombia Closes an Unsecured Revolving Credit Facility of CAD 580,000 with Private Financing Company in Colombia CI
Khiron Life Sciences Starts Providing Insurance-covered Prescriptions in Colombia MT
Khiron Edging Up as Notes NHS Reimburses Cost of Cannabis Treatment to First Zerenia Clinics UK Patient MT
Khiron Life Sciences Corp. Announces Full Reimbursement by the NHS of Costs Associated to Cannabis-Based Medication and Clinic Fees for A Patient Enrolled in Zerenia Clinics UK CI
Khiron Wins First Medical Cannabis Contract with Colombia's Largest Public Insurance Company CI
More news
1 year
0.04
Extreme 0.035
0.06
3 years
0.04
Extreme 0.035
0.60
5 years
0.04
Extreme 0.035
3.95
10 years
0.04
Extreme 0.035
4.35
More quotes
Managers TitleAgeSince
Founder 45 12-05-15
Director of Finance/CFO 57 23-04-16
Compliance Officer 62 -
Members of the board TitleAgeSince
Director/Board Member 81 18-07-16
Founder 45 12-05-15
Director/Board Member 46 07-04-30
More insiders
Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Khiron Life Sciences Corp. - Toronto S.E.